Gilotrif Approval Gives Boehringer Milestone, But Can It Compete With Tarceva?
This article was originally published in The Pink Sheet Daily
FDA approval of its first oncology drug is a victory for Boehringer Ingelheim. Now comes another challenge – a commercial battle with Roche’s Tarceva, which is firmly established across lines of therapy for EGFR-positive lung cancer patients.
You may also be interested in...
Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer’s Gilotrif/Giotrif, but the new asset is far behind competitors from AstraZeneca and Clovis.
The Japanese pharma is consolidating its U.S. operations, including the shuttering of OSI, where Tarceva initially was developed, as the cancer drug gains another indication with a companion diagnostic.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.